Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Christian, Waldhauer, Inja, Nicolini, Valeria G., Freimoser-Grundschober, Anne, Nayak, Tapan, Vugts, Danielle J., Dunn, Claire, Bolijn, Marije, Benz, Jörg, Stihle, Martine, Lang, Sabine, Roemmele, Michaele, Hofer, Thomas, van Puijenbroek, Erwin, Wittig, David, Moser, Samuel, Ast, Oliver, Brünker, Peter, Gorr, Ingo H., Neumann, Sebastian, de Vera Mudry, Maria Cristina, Hinton, Heather, Crameri, Flavio, Saro, Jose, Evers, Stefan, Gerdes, Christian, Bacac, Marina, van Dongen, Guus, Moessner, Ekkehard, Umaña, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384349/
https://www.ncbi.nlm.nih.gov/pubmed/28405498
http://dx.doi.org/10.1080/2162402X.2016.1277306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384349/
https://www.ncbi.nlm.nih.gov/pubmed/28405498
http://dx.doi.org/10.1080/2162402X.2016.1277306

Ejemplares similares